What is MGI?
MGI Tech Co., Ltd., a member of the BGI Group, operates at the intersection of biotechnology and precision medicine. The company specializes in the development and manufacturing of high-throughput genetic sequencing instruments, mass spectrometry systems, and medical imaging technologies. By providing a comprehensive suite of life science tools, MGI enables researchers and clinicians to access affordable, real-time, and actionable biological data. Its market position is defined by a vertically integrated approach, where the company controls the production of both hardware and essential consumables, ensuring high-quality standards across its global supply chain. MGI serves a diverse clientele, ranging from academic research institutions to large-scale clinical diagnostic laboratories, effectively bridging the gap between laboratory innovation and bedside application.
How much funding has MGI raised?
MGI has raised a total of $1.4B across 3 funding rounds:
Series A
$200M
Unspecified
$200M
Series B
$1B
Series A (2019): $200M with participation from CITIC Securities, Orient Securities Capital Investment, and Green Pine Capital Partners
Unspecified (2019): $200M led by Green Pine Capital Partners, Orient Securities Capital Investment, and CITIC Goldstone Capital
Series B (2020): $1B supported by CPA and IDG Capital co
Key Investors in MGI
Green Pine Capital Partners
Green Pine Capital is a venture capital firm based in Shenzhen, China, that provides investment and project management services for high-growth technology enterprises.
CITIC Securities
Founded in 1995, CITIC Securities is a leading financial services provider offering comprehensive investment banking and capital market solutions.
IDG Capital
IDG Capital is a global investment firm with a focus on private equity and venture capital, particularly in the technology and healthcare sectors.
What's next for MGI?
With the recent influx of capital, MGI is expected to prioritize the international deployment of its DNBSEQ sequencing technology and expand its footprint in key diagnostic markets. The strategic roadmap likely involves increasing R&D expenditure to refine its multi-omics integration, thereby enhancing the diagnostic utility of its platforms. Furthermore, the company is anticipated to strengthen its operational capacity to meet the rising demand for affordable healthcare tools, potentially through strategic partnerships or localized manufacturing initiatives. As MGI transitions into a more mature phase of its lifecycle, the focus will shift toward sustaining competitive advantages in the high-growth genomics sector while navigating the complexities of global regulatory environments and clinical adoption cycles.
See full MGI company page
